ABSTRACT
days in-vitro. This proliferation was significantly inhibited by an anti-HLA-class II monoclonal antibody In-vitro, CD34+ cells-derived antigen-presenting cells (APCs) were functionally capable of both direct and indirect presentation of alloantigens. Based on these findings, we hypothesize that in HSC transplantation the initial crosstalk between allogeneic T-cells and CD34+ cells may result in the increased generation of APCs that can present host alloantigens, and possibly contribute to the development of graft-vesus-host disease.
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INTRODUCTION
CD34+ cell populations in human bone marrow and peripheral blood can act as APCs and activate allogeneic T cells in vitro due to the presence of committed myeloid progenitors that constitutively express HLA, adhesion and costimulatory molecules 1, 2 . These latter molecules are upregulated on CD34+ cells upon binding to T cells, or after addition of tumor necrosis factor-α (TNF α) for 24 hours to the culture 2, 3 . Similarly, ICOS-L expression on CD34+ cells can be induced by TNFα and can act as an alternative costimulatory pathway on stem cells 4 . Moreover, the expression of costimulatory molecules identifies a subpopulation of CD34+ progenitors that differentiate into dendritic cells (DC) in liquid culture 3, 5 . CD34+ cells from cord blood (CB) also generate myeloid DCs in response to GM-CSF and
TNFα in-vitro 6, 7 , and allow the engraftment of functional DCs in NOD/SCID mice 8 .
After HSC transplantation, allogeneic donor T cells respond to host APCs and initiate graft-versus-host disease (GVHD), but also facilitate the engraftment of donor CD34+ cells 9, 10 . Experiments in NOD/SCID mice suggested an important role of CD8+ T cells in facilitating the migration, homing and engraftment of CD34+ cells, through alteration of signaling via the chemokine receptor CXCR4 11 . However, while T cells can enhance the stimulatory activity of dendritic cells 12 , the effect of donor T cells on the APC function of CD34+ cells is not known. Multiple clinical studies have shown direct correlations between CD34+ cell dose [13] [14] [15] [16] and the development of graft-versus-host disease (GVHD). Mielcarek and collegues have hypothesized that donor CD34+ APCs, or APCs derived from CD34+ cells, may contribute to the development of GVHD by indirect presentation of host-alloantigen 17 .
In this study, we show that allogeneic T cells can affect the function of CD34+ cells by inducing the proliferation and rapid differentiation of a subset of progenitors into monocytic-dendritic precursors capable of both direct and indirect alloantigen presentation. Co-transplantation of CD34+ cells and allogeneic T cells into NOD/SCID mice resulted in a better engraftment of human CD45+ cells with 
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MATERIAL AND METHODS
Flow Cytometry.
Flow cytometric analysis was performed on samples of peripheral blood (PB) and CB cells. The following fluorescein isthyocianate (FITC), or phycoerythrin (PE), or peridin chlorophyll protein (PerCP) conjugated mAbs were employed: CD34, HLA-DR, CD14, CD45, CD86, CD40, CD11c, CD33, CD1a, CD19 from Becton-Dickinson (San Jose, CA) and CD1c (BDCA-1) from Miltenyi Biotec (Auburn, CA).
Appropriate isotype controls were also utilized. Stained cells were washed twice in PBS and sample acquisition and analysis was performed within 2 hours on a FACSCaliburTM (Becton Dickinson).
Cell separation.
CB mononuclear cells (MNC) were obtained by centrifugation over Ficoll/Hypaque (Amersham Biosciences, Piscataway, NJ) gradients. Light density cells were washed twice in phosphate bufferedsaline (PBS, Cambrex, Walkersville, MD) with 1% bovine serum albumin (BSA, Sigma Chemical Co, St.
Louis, MO) and CD34 + cells were purified by MidiMACS high gradient magnetic separation column (Miltenyi Biotec). To assess the purity, aliquots of isolated CD34+ cells were restained with an anti-CD34 monoclonal antibody (mAb) FITC-conjugated (Becton-Dickinson). PB or CB T cells were immunomagnetically purified from MNC on a MidiMACS column by negative selection of non-T cells by using a Pan T Cell Isolation Kit II (Miltenyi Biotec). This kit utilizes a cocktail of biotin-conjugated mAbs against CD14, CD16, CD19, CD36, CD56, CD123 and Glycophorin A as a primary labeling reagent, and anti-biotin mAbs conjugated to microbeads, as secondary reagent. The unlabeled cells that passed through the column were then stained with an anti-CD3-FITC mAb (Becto-Dickinson) as a check for purity. Isolated CD34+, or CD3+ T cell samples were acquired on a FACS Calibur TM (Becton Dickinson) and analysed using the Cell Quest TM software (Becton Dickinson), and showed, on average, 95% cell purity. In selected experiments, CB MNC were enriched in monocytes by cell-adherence and purified T cell responders (R) were mixed with stimulators at 1:2 S/R ratio in round-bottomed 96-well plates for six days at 37° C in a 5% CO 2 humidified atmosphere. Where indicated, anti-GM-CSF and/or anti-TNFα antibodies (Pharmingen BD, San Diego, CA) were used in cell culture at 350 ng/ml and 10mg/ml, respectively, to block cytokines activity. Cells were pulsed with 1 μCi/well 3H-thymidine for 18 hours before harvest on day 6. Stimulation index (SI) was calculated for each individual experiment as: SI = cpm (T cell responders+stimulators) / cpm (T cell responders).
Stem cell proliferation and differentiation.
Freshly isolated CB CD34 + cells were cultured with irradiated (3,000 cGy) autologous CB or allogeneic peripheral blood T cells at 1:2 ratio, or in medium alone, in round-bottomed 96-well plates for six days at 37° C in a 5% CO 2 humidified atmosphere. No exogenous cytokines were added. Proliferation was measured by pulsing the cells with 1 μCi/well 3H-thymidine for 18 hours before harvest on day 6. Cells 
Indirect antigen presentation
Allogeneic PB or autologous CB MNC were incubated in 10% AB HS-RPMI at 37° C in a 5% CO 2 humidified atmosphere for 16 hours with a microbial alkaloid, staurosporin (Sigma, St.Louis, MO) at a 5 mM concentration, in order to induce the apoptotic death of the cells 19 . After washing three times, the 8 cells were evaluated by flow cytometry using an annexin V-FITC/propidium iodide (PI)-PE staining. The proportion of apoptotic cells, including early apoptotic (Annexin V+PI-) and late apoptotic (Annexin V+PI+) cells was always >95%.
After incubation with irradiated allogeneic T cells CD34+ cells were washed twice, and incubated for 48 hours with apoptotic allogeneic or autologous cells at 1:2 ratio, or with medium alone. In control experiments, CB Mo-DC were also incubated with apoptotic allogeneic cells at the same ratio. Cells were irradiated (3,000 cGy) and mixed with autologous cord blood MNC at 1:2 ratio in round-bottomed 96-well plates for six days at 37° C in a 5% CO 2 humidified atmosphere. Autologous cord blood or allogeneic peripheral blood apoptotic cells alone were mixed with responders as controls. Proliferation was measured by 3H-thymidine incorporation assay, as decribed above.
Transplantation
Immunodeficient nonobese diabetic/ltsz-scid/scid (NOD/SCID) mice were purchased from the Jackson Laboratories (Bar Harbor, ME) and were maintained as previously described 20 . Human CB purified To rule out a direct toxic effect of CTLA4-Ig on CD34+ progenitors, we performed clonogenic assays. As shown in Figure 2 (Figure 6 ). Thus, CD34-APCs that had been stimulated by alloreactive T cells could directly present alloantigen. We next hypothesized that CD34-APCs can also indirectly present alloantigen to autologous T cells. In order to test this hypothesis, we first used a microbial alkaloid, staurosporin, to induce the apoptosis in MNC from autologous CB or from allogeneic peripheral blood. CD34-APCs were then incubated with media or with apoptotic cells as a source of alloantigen for 48 hours. Cells were then washed, irradiated, and tested as stimulators for autologous CB T cell responders in a primary MLC. In four separate experiments, the autologous CB T cell response to CD34-APCs loaded with allogeneic apoptotic cells was significantly greater than the response to CD34-APCs loaded autologous apoptotic cells (p=0.02) (Figure 7) . Importantly, allogeneic apoptotic cells alone did not stimulate the T cell proliferation, demonstrating the requirement for APCs. 
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The magnitude and importance of such an amplification loop to the physiology of allogeneic BMT is yet to be determined. Interactions between donor T cells and host APCs also generate cytokines that can drive the differentiation of CD34+ cells into functional APCs, as mentioned above, and the scale of that alloreaction in all likelihood will be greater than that occurring between host T cells and donor CD34+ cells. But this amplification loop could be of significant proportions in transplants using nonmyeloablative chemo-radiotherapy, because CD34+ cells of the host that persist after conditioning may differentiate into APC following interactions with donor T cells, enhancing the anti-host response by direct presentation of alloantigen 34, 35 . These interactions could help explain recent clinical data showing that the overall rate of acute GVHD in allogeneic non-myeloablative SCT is delayed but not significantly reduced, compared to myeloablative transplants 36, 37 .
The chronic nature of the interactions between CD34-APCs and T cells in amplifying an anti-host response suggests strategies for preventing and treating GVHD that are not usually hypothesized in animal models where the onset of disease is rapid. In particular, neutralization of TNFα may be considered not only because it is a direct mediator of target organ damage 38, 39 , but for its role in the generation of mature DCs as shown in this study. Future experiments will address the ability of TNFα blockade to prevent the proliferation and differentiation of CD34-APCs at the time of transplant. Other approaches, such as blockade of B7 costimulatory pathway, could be exploited not only to induce T cell unresponsiveness, but also to reduce the number of CD34-APCs generated. Such strategies, aimed at reducing T cell responses by preventing the development of CD34-derived APCs, may eventually also prove useful to prevent graft rejection in solid organ transplantation, and to intervene in autoimmune disorders. 
Figure 7
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